Observational studyRheumatology international2025
Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of lipid parameters with the development of disease complications in patients with limited cutaneous systemic sclerosis: a prospective exploratory cohort study.Frontiers in nutrition · 2026Article
- Association of Inflammation-Based Ratios with Endothelial Dysfunction Markers and Clinical Parameters in Limited Cutaneous Systemic Sclerosis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evaluating the predictive role of endothelial dysfunction in the development of vasculopathy-mediated complications in patients with limited cutaneous systemic sclerosis (lcSSc). 38 patients with lcSSc who were naïve for vasculopathy-mediated complications, defined as absent pre-existing digital ulcers (DU), pulmonary hypertension (PH) and symptomatic atherosclerotic cardiovascular diseases, were prospectively observed during a 3-years follow-up period. At study enrolment, functional and laboratory parameters of endothelial dysfunction were assessed. Microvascular events, defined as the development of DU and PH, macrovascular events, defined as newly symptomatic atherosclerotic cardiovascular diseases, and clinical events, defined as additional interstitial lung disease (ILD), renal crisis and esophageal dysfunction, were recorded annually. 33 patients (86.8%) completed all follow-up study visits. During the follow-up period, DU, PH, carotid and vertebral artery disease and ILD occurred in eight (24.2%), one (3.0%), one (3.0%) and two patients (6.1%), respectively, without recorded renal crisis and esophageal dysfunction. Number of pathologic FMD, NMD and/or PWV values was significantly associated with the development of clinical events (p = 0.035), but was not a significant predictor for microvascular events. Number of pathologic FMD, NMD and/or PWV values was a significant predictor for disease activity assessed by EUSTAR index ≥ 2.5 at last study visit (OR 5.47 [95% CI 1.01-29.03], p = 0.049). Distinct endothelial dysfunction may promote the development of disease complications and disease activity in patients with lcSSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.